# Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

> **NCT03702894** · PHASE1 · COMPLETED · sponsor: **Pharmtechnology LLC** · enrollment: 56 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Clavamox
- **DRUG:** Augmentin®

## Key facts

- **NCT ID:** NCT03702894
- **Lead sponsor:** Pharmtechnology LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-21
- **Primary completion:** 2018-10-08
- **Final completion:** 2018-10-08
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03702894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03702894, "Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03702894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*